Literature DB >> 8037202

A multicenter study on genotype-phenotype correlations in the fragile X syndrome, using direct diagnosis with probe StB12.3: the first 2,253 cases.

F Rousseau1, D Heitz, J Tarleton, J MacPherson, H Malmgren, N Dahl, A Barnicoat, C Mathew, E Mornet, I Tejada.   

Abstract

We report the results of a 14-center collaborative study of genotype-phenotype correlations in 318 fragile X families; these families comprised 2,253 individuals, 1,344 of whom carried a fragile X mutation and 693 of whom had a typical full fragile X mutation. This study demonstrates that direct DNA diagnosis establishes the genotype at the FRAXA-FMR-1 locus. There was a significantly higher prevalence of "mosaic" cases among males who carry a full mutation (12%) than among females who carry a full mutation (6%); the mosaic males had a larger expansion than did the mosaic females. Mental status of premutated individuals did not differ from that of those with a normal genotype. Both the abnormal methylation of the FMR-1-EagI site and the size of the expansion were highly correlated with cytogenetics, facial dysmorphism, macroorchidism, and mental retardation (MR). Among female carriers of a full mutation, those with MR had significantly larger expansion than did those without MR. Among 164 independent couples, 3 unrelated husbands carried a premutation that suggests that the prevalence of fragile X premutations in the general population is approximately 0.9% of the X chromosomes. Our data validate the use of direct DNA testing for fragile X diagnosis as well as for carrier identification and support and complete the established relationships among the DNA results and the cytogenetic, physical, and psychological aspects of the disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8037202      PMCID: PMC1918361     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  34 in total

1.  Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome.

Authors:  I Oberlé; F Rousseau; D Heitz; C Kretz; D Devys; A Hanauer; J Boué; M F Bertheas; J L Mandel
Journal:  Science       Date:  1991-05-24       Impact factor: 47.728

2.  Fragile X genotype characterized by an unstable region of DNA.

Authors:  S Yu; M Pritchard; E Kremer; M Lynch; J Nancarrow; E Baker; K Holman; J C Mulley; S T Warren; D Schlessinger
Journal:  Science       Date:  1991-05-24       Impact factor: 47.728

3.  Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n.

Authors:  E J Kremer; M Pritchard; M Lynch; S Yu; K Holman; E Baker; S T Warren; D Schlessinger; G R Sutherland; R I Richards
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

4.  Implications of fragile X expression in normal males for the nature of the mutation.

Authors:  D H Ledbetter; S A Ledbetter; R L Nussbaum
Journal:  Nature       Date:  1986 Nov 13-19       Impact factor: 49.962

5.  Fragile Xq27.3 in female heterozygotes for the Martin-Bell syndrome.

Authors:  T Webb; P A Jacobs
Journal:  J Med Genet       Date:  1990-10       Impact factor: 6.318

6.  Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.

Authors:  A J Verkerk; M Pieretti; J S Sutcliffe; Y H Fu; D P Kuhl; A Pizzuti; O Reiner; S Richards; M F Victoria; F P Zhang
Journal:  Cell       Date:  1991-05-31       Impact factor: 41.582

7.  Preventive screening for the fragile X syndrome.

Authors:  G Turner; H Robinson; S Laing; S Purvis-Smith
Journal:  N Engl J Med       Date:  1986-09-04       Impact factor: 91.245

8.  Carrier detection and X-inactivation studies in the fragile X syndrome. Cytogenetic studies in 63 obligate and potential carriers of the fragile X.

Authors:  K B Nielsen; N Tommerup; H Poulsen; P Jacobsen; B Beck; M Mikkelsen
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

9.  Absence of expression of the FMR-1 gene in fragile X syndrome.

Authors:  M Pieretti; F P Zhang; Y H Fu; S T Warren; B A Oostra; C T Caskey; D L Nelson
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

10.  Mental status and fragile X expression in relation to FMR-1 gene mutation.

Authors:  B B de Vries; A M Wiegers; E de Graaff; A J Verkerk; J O Van Hemel; D J Halley; J P Fryns; L M Curfs; M F Niermeijer; B A Oostra
Journal:  Eur J Hum Genet       Date:  1993       Impact factor: 4.246

View more
  62 in total

1.  Resolution of spatial and temporal visual attention in infants with fragile X syndrome.

Authors:  Faraz Farzin; Susan M Rivera; David Whitney
Journal:  Brain       Date:  2011-11       Impact factor: 13.501

2.  Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.

Authors:  F Tassone; R J Hagerman; A K Taylor; L W Gane; T E Godfrey; P J Hagerman
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

3.  Arousal modulation in females with fragile X or Turner syndrome.

Authors:  Jane Roberts; Michèle M M Mazzocco; Melissa M Murphy; Rudolf Hoehn-Saric
Journal:  J Autism Dev Disord       Date:  2007-03-06

4.  FMR1 gene mutations in patients with fragile X syndrome and obligate carriers: 30 years of experience in Chile.

Authors:  Lorena Santa María; Solange Aliaga; Víctor Faundes; Paulina Morales; Ángela Pugin; Bianca Curotto; Paula Soto; M Ignacia Peña; Isabel Salas; M Angélica Alliende
Journal:  Genet Res (Camb)       Date:  2016-06-28       Impact factor: 1.588

5.  Mental status of females with an FMR1 gene full mutation.

Authors:  B B de Vries; A M Wiegers; A P Smits; S Mohkamsing; H J Duivenvoorden; J P Fryns; L M Curfs; D J Halley; B A Oostra; A M van den Ouweland; M F Niermeijer
Journal:  Am J Hum Genet       Date:  1996-05       Impact factor: 11.025

6.  The DNA replication program is altered at the FMR1 locus in fragile X embryonic stem cells.

Authors:  Jeannine Gerhardt; Mark J Tomishima; Nikica Zaninovic; Dilek Colak; Zi Yan; Qiansheng Zhan; Zev Rosenwaks; Samie R Jaffrey; Carl L Schildkraut
Journal:  Mol Cell       Date:  2013-11-27       Impact factor: 17.970

Review 7.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome.

Authors:  Laura Greiss Hess; Sarah E Fitzpatrick; Danh V Nguyen; Yanjun Chen; Kimberly N Gaul; Andrea Schneider; Kerrie Lemons Chitwood; Marwa Abd Al Azaim Eldeeb; Jonathan Polussa; David Hessl; Susan Rivera; Randi J Hagerman
Journal:  J Dev Behav Pediatr       Date:  2016-10       Impact factor: 2.225

9.  Autism spectrum disorder in fragile X syndrome: a longitudinal evaluation.

Authors:  R Nick Hernandez; Rachel L Feinberg; Rebecca Vaurio; Natalie M Passanante; Richard E Thompson; Walter E Kaufmann
Journal:  Am J Med Genet A       Date:  2009-06       Impact factor: 2.802

10.  Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population.

Authors:  D C Crawford; K L Meadows; J L Newman; L F Taft; D L Pettay; L B Gold; S J Hersey; E F Hinkle; M L Stanfield; P Holmgreen; M Yeargin-Allsopp; C Boyle; S L Sherman
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.